This study evaluated sonidegib, a hedgehog pathway inhibitor, for the treatment of advanced or recurrent basal cell carcinoma. The analysis assessed response rates, duration of response, and tolerability, providing updated efficacy data for this targeted therapy in BCC management.

Sonidegib demonstrates meaningful clinical efficacy in advanced or recurrent BCC that is not amenable to surgery or radiation.

Hedgehog pathway inhibitors remain an important systemic option for locally advanced BCC, though long-term tolerability should be monitored.